Numbers of Authorized and Outstanding Shares Reduced on a 1-for-5 Basis Iselin NJ, May 31, 2005 – Pharmos Corporation (Nasdaq: PARS) today announced that its Board of Directors has approved a one-for-five reverse split of its common stock, effective today, May 31, 2005. Beginning today, the Company’s common stock will trade for twenty trading days under a new ticker symbol on Nasdaq: PARSD. As a result […]
Iselin, NJ and Rehovot, Israel, May 23, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today Seth Kindler, M.D., Medical Director of Pharmos, will present at the Bio-Tech Israel 2005 Conference in Tel Aviv at the David Intercontinental Hotel at 4:45 p.m. Eastern European Daylight Time on Tuesday, May 24, 2005. The presentation will outline the Company’s research and development focus utilizing its rich library of proprietary […]
Office of the Chief Scientist Awards US $1.3 Million to Fund Development of Cannabinoid Compounds Iselin NJ, May 3, 2005 – Pharmos Corporation (Nasdaq: PARS) today announced it has been awarded a grant of US$ 1.3 million by the Office of the Chief Scientist (OCS) of Israel’s Ministry of Industry and Trade. The funds have been granted for the development of drug candidates from the Company’s […]
Iselin NJ, April 28, 2005 – Pharmos Corporation (Nasdaq: PARS) today reported financial results for the first quarter ended March 31, 2005. In the first quarter Pharmos received a gross milestone payment of $12.3 million from a former marketing partner. As a result of this non- recurring milestone event, the Company recorded positive income and cash flow for the quarter. The recorded net income was $6.7 […]
Appoints Dr. Howard Grossberg as Vice President, Drug Development Iselin NJ, April 20, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today the appointment of Howard Grossberg, M.D. as Vice President of Drug Development responsible for all post-discovery drug development, and of Iris Alroy, Ph.D. as Vice President of Research. Dr. Alroy will head the Company’s research efforts at its Rehovot, Israel facility. The Company also announced […]
Iselin NJ, March 9, 2005 – Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve month period ended December 31, 2004. The net loss for the year increased to $22.0 million, or $0.24 per share in 2004 compared to a net loss of $18.5 million, or $0.27 per share in 2003. Cash and cash equivalents totaled $54.0 million at December 31, […]
Iselin NJ, February 28, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today that it will release financial results for the fourth quarter and full year 2004 on March 9, 2005. Gad Riesenfeld, PhD, President and COO, will host a conference call on the same day at 11:00 AM, EST to discuss recent developments at the Company. In addition to discussing fourth quarter and full year 2004 […]
Iselin NJ, January 25, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today that the Company has received a gross milestone payment of $12.1 million from Bausch & Lomb (NYSE: BOL), its former marketing partner for ophthalmology products. The milestone payment was triggered by Bausch & Lomb’s commercial launch of Zylet™, which was approved for marketing by the FDA on December 15, 2004. Zylet is part of […]